Riccardin C, a bisbibenzyl compound from Primula macrocalyx

Fingerprinting of Secondary Metabolites of Liverworts: Chemosystematic Approach

“…Liverworts are abundant sources of new carbon skeletons of natural sesquiterpenoids, which are relatively rare groups of naturally occurring compounds. These are seco-africanes (15)(16)(17), noraristolanes (18,19), 1,10-seco-aromadendranes (20, 21), 2,3-seco-aromadendranes (22,23), aromadendraneguaiane dimers (24), seco-cuparanes (25), cuparane dimers (26) The most characteristic compounds isolated from the Marchantiophyta are bis-bibenzyls (81-86). In particular, Marchantia species (Marchantiaceae) are a rich source of these compounds, especially belonging to the marchantin type group (e.g., 81; 18).…”

Solvothermal Synthesis of CuFe2O4@rGO: Efficient Catalyst for C‐O Cross Coupling and N‐arylation Reaction under Ligand‐Free Condition

“…These reactions play a significant role in the synthesis of a variety of biologically active pharmaceutical ingredients and natural products . Diaryl ethers are used in the synthesis of compounds having antibiotic activity such as antitumor riccardin C, bouvardin, hormone thyroxin, antiviral peptide K‐133 and antibiotic piperazinomycin . Some N ‐heterocyclic compounds such as N ‐aryl indoles and imidazoles are widely used as antipsychotic,, anti‐allergic, antiestrogen, and analgesic agents .…”

A Corey–Seebach Macrocyclisation Strategy for the Synthesis of Riccardin C and an Unnatural Macrocyclic Bis(bibenzyl) Analogue

“…Macrocyclic bis(bibenzyl) natural products have largely been found in liverworts and other bryophytes,, with riccardin C ( 10 ) alone in being identified in a higher plant species , . In nature, all of these compounds are derived from lunularin ( 4 ; Figure ) .…”

“…The largest familial group is based on macrocyclic core 2 , and has riccardin C ( 10 ) at its helm (Figures and ) , . A popular synthetic target for many years, riccardin C recently gained prominence when a screening seeking new leads against cardiovascular disease revealed that it acted as an agonist for the cholesterol‐regulating liver X receptor LXRα and an antagonist for LXRβ .…”